Evidence map›Paper›PMID 41600942›Full record

ArticleVaccines2025

National Near Real-Time Vaccine Effectiveness Against COVID-19 Severe Outcomes Using the Screening Method Among Older Adults Aged ≥50 Years in Canada.

Robert MacTavish, Andreea Slatculescu, Dylan Ermacora, Katarina Vukovojac, Tanner Noth, Natalie Ward, Kathleen Laskoski, Daniela Fleming, Baanu Manoharan, Julie Laroche and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Robert MacTavishVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Andreea SlatculescuVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.ORCID 0000-0001-5234-2211
Dylan ErmacoraVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Katarina VukovojacVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Tanner NothVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Natalie WardVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Kathleen LaskoskiVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Daniela FlemingVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Baanu ManoharanVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Julie LarocheVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.
Aissatou FallVaccine Effectiveness Surveillance Program (VESPa), Vaccine Coverage and Effectiveness Surveillance Division, Centre for Immunization Surveillance and Programs, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, 785 Carling Ave, Ottawa, ON K1A 0K9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CanadaCOVID-19 vaccine effectivenessolder adultsSARS-CoV-2screening methodsevere COVID-19 outcomessurveillance

Identifiers

PMID41600942
PMCPMC12846497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.